FCS Press Releases

A clinical study co-authored by Ernesto Bustinza-Linares, MD has found that proteome testing leads to targeted treatment for NSCLC.

Lucio N. Gordan, MD discusses novel treatments for multiple myeloma in national broadcast hosted by Darzalex.

Nurses and leaders from Florida Cancer Specialists & Research Institute are featured presenters at the 2024 Oncology Nursing Society Congress.

FCS is pleased to share that its financial performance for the first two months of 2024 has surpassed the statewide practice’s budget.

Clinical research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) will be highlighted at the American Association for Cancer Research 2024 Annual Meeting in San Diego as scientists, clinicians and other health care professionals and stakeholders from all over the world gather to share the latest advances in cancer science and medicine.

Pharmacy leaders from Florida Cancer Specialists & Research Institute share expertise and best practices at the NCODA 2024 Spring Forum.

Pharmacy leaders from Florida Cancer Specialists & Research Institute share expertise and best practices at the NCODA 2024 Spring Forum.

Core Ventures, Florida Cancer Specialists & Research Institute’s MSO, announces the formation of a new real-world evidence and analytics company, Vita Nova Insights(SM).

FCS, in partnership with Research to Practice, will host the Third Annual National General Medical Oncology Summit in Miami, Florida.

FCS and its MSO, Core Ventures, have leveraged partnerships in a unified approach to create a solution to remain operational in the wake of the Change Healthcare shutdown in February 2024.

Florida Cancer Specialists & Research Institute has implemented contingency plans in response to the Change Healthcare outage.

Jacob Barish, MD now seeing patients at FCS Lake Nona Cancer Center and FCS Kissimmee.

FCS has opened a new state-of-the-art facility at 2824 Enterprise Road, Orange City, FL 32763-8428 to provide comprehensive treatments and a variety of services to adults with cancer, blood disorders and other diseases.

FCS continues to advance the treatment of gastrointestinal and genitourinary cancers, as evidenced by participation at two global gatherings held this month and sponsored by the American Society of Clinical Oncology (ASCO®).

A best practices program developed at Florida Cancer Specialists & Research Institute (FCS) has been shown to improve outcomes for adult patients prescribed selinexor for the treatment of relapsed/refractory multiple myeloma (RRMM).

Senior Vice President & Data Officer Trevor Heritage, PhD will share learnings gained from the statewide practice’s development of an innovative propriety precision oncology platform at the Precision Medicine World Conference (PMWC® 2024) being held this month in Santa Clara, California.